RxDoctor Payments Data

Daniel Rontal, MD

Otolaryngology · Royal Oak, MINPI 1831152610

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,635 of the $11,600 with a category attached, or 65.8%. Intersect ENT, Inc. accounts for 85.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $9,888 and has fallen 98.3% since, to $171 in 2025. Among otolaryngology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,600in general payments, 2019–2025

Across 79 payments — averaging $146.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intersect ENT, Inc.$10K
  • Optinose US, Inc.$321
  • Organogenesis Inc.$238
  • Stryker$194
  • Hologic Sales And Service, LLC$164
  • GSK$121
  • plus $640 from 16 others
$40,365in research payments, 2019–2025

Across 3 payments — averaging $13,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurent Medical Limited$40K

What the payments were for

  • Consulting fees$751%
  • Speaking & faculty fees$7,63566%
  • Travel & lodging$1,0369%
  • Food & beverage$2,85425%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,600 in reported general payments places this provider in the 90th percentile of 257 otolaryngology providers in Michigan.

See all otolaryngology providers in Michigan

Medicare billing

Part B allowed, 2024
$233,032
Medicare patients
874
Services billed
2,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate243$18,849
Olopatadine Hcl41$4,362
Azelastine Hcl112$3,195
Cevimeline Hcl15$2,756
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth23$2,555
Ipratropium Bromide75$2,442
Omeprazole92$1,789
Pantoprazole Sodium66$1,503
Fluticasone Propionate85$1,455
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav98$893
Famotidine28$580
Fluocinolone Acetonide Oil19$517
Montelukast Sodium13$431
Triamcinolone Acetonide37$377
Clotrimazole12$360

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →